Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2026-01-06 00:00:00 ET · period of report 2026-01-02 · accession 0001225471-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-06 | 2026-01-02 | REGN | SING GEORGE L | Dir | A - Grant | $0.00 | +155 | 31.0K | +0.5% | $0 |
| D | 2026-01-06 | 2026-01-02 | REGN | SING GEORGE L | Dir | A - Grant | $0.00 | +1,962 | 1,962 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-02 | A | A | 155 | $0.00 | 31,007 | D | — | — | |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-01-02 | A | A | 1,962 | $0.00 | 1,962 | D | $772.76 · — to 2036-01-02 | 1,962 Common Stock | (F2) On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |